BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Stock chart, upward arrow

Biggest gainers and losers for the week of Oct. 11-15, 2021

Oct. 15, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More

Med-tech gainers and losers for Oct. 11-15, 2021

Oct. 15, 2021
The top 10 med-tech stock gainers and losers for the week.
Read More
Business people with hands atop a digital globe

Q3 on top with strong med-tech M&As and record deal volume

Oct. 14, 2021
By Karen Carey
The speed at which the med-tech industry is completing mergers and acquisitions in 2021 is something quite contrary to the typical slowdown seen when the financing window is open wide. But yet, a total of 477 M&As valued at $109.18 billion have closed in the first three quarters this year, more in volume and value than for each of the previous three years, and during what appears to be the second best year on record for financings. The sector has already raised $42 billion. On the other hand, the lack of disclosed terms continues to weigh heavy on deals, making them appear on paper to be significantly below recent years, down by about 73% in comparison with 2020’s first three quarters. Importantly, though, numbers of completed deals for every quarter and for the combined nine months are at their highest levels ever.
Read More
M&A cityscape

M&As recovering as biopharma deals slide past 2020

Oct. 12, 2021
By Karen Carey
With a growing number of deals worth $1 billion or more, 2021 values are slowly inching past 2020’s record year, as mergers and acquisitions also move higher, indicating a potentially stronger second half of the year.
Read More
International currency symbols

Despite record IPOs and VC rounds, med-tech financings tracking below 2020

Oct. 12, 2021
By Karen Carey
With more than two months of financings yet to record for the year, the med-tech industry has already raised more money through IPOs and venture capital rounds than in each of the prior four years. But fewer funds collected through follow-on offerings and private placements puts 2021 about 30% below the full-year total for 2020, which was $59.7 billion.
Read More

Money raised by biopharma: 2021 vs. 2020 vs. 2019

Oct. 8, 2021
Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-Oct. 7, 2021

Oct. 8, 2021
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Hand holding IPO, financial icons

Biopharma money raised by quarter in 2021 (US$M)

Oct. 8, 2021
Biopharma money raised to-date and by quarter in 2021, including public, private and other financings.
Read More

BioWorld and Nasdaq stock indices

Oct. 8, 2021
These graphs compare the performance of the biotech stocks for all of 2021 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More
Stock chart, upward arrow

Biggest gainers and losers for the week of Oct. 4-8, 2021

Oct. 8, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More
Previous 1 2 … 201 202 203 204 205 206 207 208 209 … 309 310 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 23, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 21, 2026
  • Green arrow on blue abstract background

    Psychedelic space expanding on Trump’s EO

    BioWorld
    Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
  • Illustration of metastatic cancer

    At AACR: Epigenetic fingerprints in metastases track tumor origin

    BioWorld
    When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
  • In the clinic for April 21, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing